Recent studies of lung adenocarcinoma have suggested that molecular profiling could be of value in future clinical decision making by providing clues about, e.g., treatment response to EGFR inhibitors [17,20,47,48]. The gene discussed is EGFR; the disease is lung adenocarcinoma.